Article

Segment 4- Nonadherence Caused by a Lack of Access

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed. “It’s certainly happening for ipilimumab,” said Dr Ribas. “In places like the county hospital it’s hard to find any patient who has been on ipilimumab because it’s not being approved for administration even though it’s an FDA-approved drug and even though there are 2 randomized trials that demonstrated improvement in survival.”

Related Videos
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Pierluigi Porcu, MD
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Joseph Saseen, PharmD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo